Month: June 2021

Jun 30 2021

Uncategorized

Pfizer’s neuroscience spinout scores in schizophrenia – BioPharma Dive

by Clinical Editor

No Comments

Pfizer’s neuroscience spinout scores in schizophrenia  BioPharma Dive Cerevel soars on first data for muscarinic schizophrenia drug –  pharmaphorum Cerevel Therapeutics Sees Positive Results From Trial for Schizophrenia Treatment  MarketWatch Cerevel Therapeutics Announces...

Jun 30 2021

Uncategorized

Cerevel’s stock rockets up on release of early data in schizophrenia, followed by an offering – Endpoints News

by Clinical Editor

No Comments

Cerevel’s stock rockets up on release of early data in schizophrenia, followed by an offering  Endpoints News

Jun 30 2021

Uncategorized

Cerevel soars on first data for muscarinic schizophrenia drug

by Clinical Editor

No Comments

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, …

Jun 30 2021

Uncategorized

Cerevel Doubles on Progress With Schizophrenia Drug Test

by Clinical Editor

No Comments

Cerevel’s treatment candidate for schizophrenia in testing showed meaningful improvement over placebo. The stock is higher.

Jun 30 2021

Uncategorized

Cerevel stock doubles on success of phase 1b schizophrenia trial

by Clinical Editor

No Comments

Cerevel Therapeutics’ schizophrenia prospect has impressed in a phase 1b clinical trial, triggering a 136% surge in the stock price. The Pfizer spinout is now preparing to move into phase...

Jun 30 2021

Uncategorized

Deep brain stimulation for treating schizophrenia

by Clinical Editor

No Comments

Managing schizophrenia is a lifelong process, and although there’s no cure, it can be treated with medications and therapy. However, one-fifth to one-half of patients with schizophrenia who show …

Jun 30 2021

Uncategorized

Risk for dementia diagnosis up for seniors with schizophrenia

by Clinical Editor

No Comments

Older adults with schizophrenia have an increased risk for receiving a diagnosis of dementia compared with those without serious mental illness (SMI), according to a study published in the June...

Jun 29 2021

Uncategorized

Care Disparities Seen for COVID-19 Patients With, Without Schizophrenia – HealthDay News

by Clinical Editor

No Comments

Care Disparities Seen for COVID-19 Patients With, Without Schizophrenia  HealthDay News

Jun 29 2021

Uncategorized

Cerevel Therapeutics Stock Shoots Higher As Schizophrenia Treatment Tops Placebo On Antipsychotic Activity

by Clinical Editor

No Comments

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) has announced results from its Phase 1b trial of CVL-231 in adult patients with schizophrenia. CVL-231 was generally well-tolerated, and …

Jun 29 2021

Uncategorized

Deep brain stimulation for treating schizophrenia

by Clinical Editor

No Comments

Managing schizophrenia is a lifelong process, and although there’s no cure, it can be treated with medications and therapy. However, one-fifth to one-half of patients with schizophrenia who show …